Clinical Trial Detail

NCT ID NCT02864290
Title A Study to Evaluate Escalating Doses of AGS62P1 Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

acute myeloid leukemia

Therapies

AGS62P1

Age Groups: senior adult

No variant requirements are available.